A NEW ANTISEPTIC - FURFURYLAMINE BIGUANIDINE DERIVATIVE SYNTHESIS AND ITS EFFECT ON MULTI-DRUG RESISTANT ACINETOBACTER BAUMANNII STRAINS

Abstract

Objective: The number of antiseptics used in a hospital environment are limited, hence some of them are restricted because of resistance. Furfurylamine biguanidine HCl (FBC) and furfurylamine biguanidine acetate (FBA) are new chemical antiseptics that have been developed by our group for the first time. With this research, we target to examine and investigate the antibacterial features of the new generation biguanidine derivatives against the multi-drug resistant Acinetobacter baumannii (MDRAb) strains. Method: Bactericidal efficacy was examined as per the DIN EN 1040 (DIN EN 1040, 2005) standard. A 5 log decrease in bacterial density was accepted as efficient. By the agar well diffusion method, the effects of FBC and FBA on the resistant Acinetobacter strains were investigated. Result: FBC and FBA were found as bactericidal efficient with 5 log decrease in bacterial density. FBC and FBA formed an inhibition zone of at least 15 mm in the 20 separate MDRAb strain disc diffusion tests. Conclusion: As FBC and FBA were isolated for the first time, they were deemed effective against MDRAb strains.